Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: A systematic review

23Citations
Citations of this article
70Readers
Mendeley users who have this article in their library.

Abstract

During these last years, there have been an increased number of new drugs for non-small cell lung cancer (NSCLC), with a growing financial effect on patients and society. The purpose of this article was to review the economics of first-line and maintenance NSCLC treatments. We reviewed economic analyses of NSCLC therapies published between 2004 and 2014. In first-line settings, in unselected patients with advanced NSCLC, the cisplatin gemcitabine doublet appears to be cost-saving compared with other platinum doublets. In patients with nonsquamous NSCLC, the incremental cost-effectiveness ratios (ICERs) per life-year gained (LYG) were $83,537, $178,613, and more than $300,000 for cisplatin-pemetrexed compared with, respectively, cisplatin-gemcitabine, cisplatin-carboplatin-paclitaxel, and carboplatin-paclitaxel-bevacizumab. For all primary chemotherapy agents, use of carboplatin is associated with slightly higher costs than cisplatin. In all the analysis, bevacizumab had an ICER greater than $150,000 per quality-adjusted life-year (QALY). In epidermal growth factor receptor mutated advanced NSCLC, compared with carboplatin-paclitaxel doublet, targeted therapy based on testing available tissue yielded an ICER of $110,644 per QALY, and the rebiopsy strategy yielded an ICER of $122,219 per QALY. Compared with the triplet carboplatin-paclitaxel-bevacizumab, testing and rebiopsy strategies had ICERs of $25,547 and $44,036 per QALY, respectively. In an indirect comparison, ICERs per LYG and QALY of erlotinib versus gefitinib were $39,431 and $62,419, respectively. In anaplastic lymphoma kinase-positive nonsquamous advanced NSCLC, the ICER of first-line crizotinib compared with that of chemotherapy was $255,970 per QALY. For maintenance therapy, gefitinib had an ICER of $19,214 per QALY, erlotinib had an ICER of $127,343 per LYG, and pemetrexed had an ICER varying between $183,589 and $205,597 per LYG. Most recent NSCLC strategies are based on apparently no cost-effective strategies if we consider an ICER below $50,000 per QALY an acceptable threshold. We need, probably on a countrywide level, to have a debate involving public health organizations and pharmaceutical companies, as well as clinicians and patients, to challenge the rising costs of managing lung cancer.

References Powered by Scopus

2nd ESMO Consensus Conference on Lung Cancer: Non-small-cell lung cancer first-line/second and further lines in advanced disease

219Citations
N/AReaders
Get full text

Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting

154Citations
N/AReaders
Get full text

A trial-based assessment of the cost-utility of Bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer

89Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China

51Citations
N/AReaders
Get full text

MicroRNA-200c inhibits the metastasis of non-small cell lung cancer cells by targeting ZEB2, an epithelial-mesenchymal transition regulator

39Citations
N/AReaders
Get full text

Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer – final results from the prospective German TLK cohort study

22Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Chouaïd, C., Crequit, P., Borget, I., & Vergnenegre, A. (2014, December 15). Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: A systematic review. ClinicoEconomics and Outcomes Research. Dove Medical Press Ltd. https://doi.org/10.2147/CEOR.S43328

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 33

75%

Researcher 8

18%

Professor / Associate Prof. 2

5%

Lecturer / Post doc 1

2%

Readers' Discipline

Tooltip

Medicine and Dentistry 25

63%

Pharmacology, Toxicology and Pharmaceut... 8

20%

Economics, Econometrics and Finance 5

13%

Computer Science 2

5%

Save time finding and organizing research with Mendeley

Sign up for free